» Articles » PMID: 37376598

Significant Broad-Spectrum Antiviral Activity of Bi121 Against Different Variants of SARS-CoV-2

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2023 Jun 28
PMID 37376598
Authors
Affiliations
Soon will be listed here.
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has so far infected 762 million people with over 6.9 million deaths worldwide. Broad-spectrum viral inhibitors that block the initial stages of infection by reducing virus binding and proliferation, thereby reducing disease severities, are still an unmet global medical need. We studied Bi121, which is a standardized polyphenolic-rich compound isolated from , against recombinant vesicular stomatitis virus (rVSV)-pseudotyped SARS-CoV-2S (mutations in the spike protein) of six different variants of SARS-CoV-2. Bi121 was effective at neutralizing all six rVSV-ΔG-SARS-CoV-2S variants. The antiviral activity of Bi121 was also assessed against SARS-CoV-2 variants (USA WA1/2020, Hongkong/VM20001061/2020, B.1.167.2 (Delta), and Omicron) in Vero cells and HEK-ACE2 cell lines using RT-qPCR and plaque assays. Bi121 showed significant antiviral activity against all the four SARS-CoV-2 variants tested, suggesting a broad-spectrum activity. Bi121 fractions generated using HPLC showed antiviral activity in three fractions out of eight against SARS-CoV-2. The dominant compound identified in all three fractions using LC/MS/MS analysis was Neoilludin B. In silico structural modeling studies with Neoilludin B showed that it has a novel RNA-intercalating activity toward RNA viruses. In silico findings and the antiviral activity of this compound against several SARS-CoV-2 variants support further evaluation as a potential treatment of COVID-19.

Citing Articles

Unlocking the therapeutic potential of natural extract: A scoping review.

Reina B, Malheiros S, Vieira S, Ferreira de Andrade P, Dovigo L Heliyon. 2024; 10(23):e40554.

PMID: 39654721 PMC: 11625261. DOI: 10.1016/j.heliyon.2024.e40554.


Reply to Kulić, Ž. Comment on "Subhadra et al. Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2. 2023, , 1299".

Subhadra B, Agrawal R, Pal V, Chenine A, Mattathil J, Singh A Viruses. 2023; 15(11).

PMID: 38005945 PMC: 10674820. DOI: 10.3390/v15112269.


Comment on Subhadra et al. Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2. 2023, , 1299.

Kulic Z Viruses. 2023; 15(11).

PMID: 38005944 PMC: 10675578. DOI: 10.3390/v15112268.


From Alpha to Omicron: How Different Variants of Concern of the SARS-Coronavirus-2 Impacted the World.

Andre M, Lau L, Pokharel M, Ramelow J, Owens F, Souchak J Biology (Basel). 2023; 12(9).

PMID: 37759666 PMC: 10525159. DOI: 10.3390/biology12091267.

References
1.
Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X . PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017; 45(W1):W356-W360. PMC: 5793840. DOI: 10.1093/nar/gkx374. View

2.
Tabibzadeh A, Esghaei M, Soltani S, Yousefi P, Taherizadeh M, Safarnezhad Tameshkel F . Evolutionary study of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emerging coronavirus: Phylogenetic analysis and literature review. Vet Med Sci. 2020; 7(2):559-571. PMC: 7753621. DOI: 10.1002/vms3.394. View

3.
Nakamura M, Fukunaga Y, Sasa K, Ohtoshi Y, Kanaori K, Hayashi H . Pyrene is highly emissive when attached to the RNA duplex but not to the DNA duplex: the structural basis of this difference. Nucleic Acids Res. 2005; 33(18):5887-95. PMC: 1258169. DOI: 10.1093/nar/gki889. View

4.
Bafna K, Cioffi C, Krug R, Montelione G . Structural similarities between SARS-CoV2 3CL and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals. Front Chem. 2022; 10:948553. PMC: 9638714. DOI: 10.3389/fchem.2022.948553. View

5.
Vilar S, Cozza G, Moro S . Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem. 2008; 8(18):1555-72. DOI: 10.2174/156802608786786624. View